Asperuloside (ASP) is an iridoid glycoside that is extracted from Eucommia leaves. Eucommia is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.
Cite this item
Nakamura, A., Yokoyama, Y., Tanaka, K., Benegiamo, G., Hirayama, A., Zhu, Q., Kitamura, N., Sugizaki, T., Morimoto, K., Itoh, H., Fukuda, S., Auwerx, J., Tsubota, K., & Watanabe, M. (2020). Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling. Iscience, 23(9), Article 101522. https://doi.org/10.1016/j.isci.2020.101522
Click Copy to copy the citation, or select the text manually.
1-s2.0-S2589004220307203-main.pdf
Publisher's Version
Published version
openaccess
CC BY-NC-ND
6.09 MB
Adobe PDF
dc318a59634c89e5cd2b81b42cbf57b1